



Contact:

Douglas Doerfler
Chief Executive Officer
MaxCyte, Inc.
(301) 944-1700

For Immediate Release

**MaxCyte to Be Featured at the BIO Emerging Company Investor
Forum, Rodman & Renshaw Techvest 6th Annual
Healthcare Conference and the Mid-Atlantic Venture Conference**

Gaithersburg, MD, October 12, 2004 – MaxCyte, Inc., a clinical stage therapeutic company and pioneer in clinical scale, non-viral cell loading systems, announced Douglas A. Doerfler, President and CEO, will be presenting at the BIO Emerging Company Investor Forum in San Francisco, Palace Hotel, Sea Cliff Room on Thursday, October 14, 2004, at 12:10PM PDT, the Rodman & Renshaw Techvest 6th Annual Healthcare Conference in New York City, Waldorf-Astoria, Metropolitan Room on Tuesday, October 26, 2004, at 4:35PM EDT, and the Mid-Atlantic Venture Conference in Philadelphia, Pennsylvania Convention Center at 10:41AM EDT on Wednesday, October 27, 2004.

Mr. Doerfler will provide a brief corporate overview and discuss the company's preclinical and clinical product candidates, partnering activities, and enabling technology for therapeutic development and biotherapeutic manufacturing.

About MaxCyte

MaxCyte is a clinical stage therapeutics company developing both proprietary and partnered therapeutics. MaxCyte's proprietary cell loading technology is scalable, highly efficient, reproducible and reduces regulatory risk in *ex vivo* cell loading. Cell loading technology is fundamental to developing cell-based therapeutics. MaxCyte's pipeline includes one product in Phase I/II clinical trials for the treatment of Chronic Lymphocytic Leukemia (CLL) and several preclinical candidates to treat a variety of diseases with unmet needs. The company also offers its powerful technology to partners so that they can take advantage of its advanced capabilities for cell-based therapeutic development and biotherapeutic manufacturing. Therapeutic applications include non-viral gene delivery and delivery of a therapeutic drug or large proteins; current partners are working to develop therapeutics for pulmonary disease, congenital heart disease and oncology. MaxCyte's solution for biotherapeutic manufacturing allows the scalable production of viral vectors, making possible all phases of the development process, from pre-clinical through clinical trials and through to product manufacturing.

For more information including the referenced abstract, visit <http://www.maxcyte.com>.

This press release may contain, in addition to historical information, certain forward-looking statements that involve risks and uncertainties. Such statements reflect management's current views and are based on certain assumptions. Actual results could differ materially from those currently anticipated as a result of a number of factors, including risks and uncertainties.

###